Cogeco Peer 1 Changes Name to Aptum Technologies; Adds New Services to Enhance and Expand Hybrid Cloud Offerings
19.8.2019 15:00:00 EEST | Business Wire | Press release
Cogeco Peer 1, a managed hosting and cloud services provider, today announced it has changed its name to Aptum Technologies. The move follows the April 2019, acquisition of Cogeco Peer 1 by Digital Colony, a global investment firm dedicated to strategic opportunities in digital infrastructure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190819005121/en/
Susan Bowen, CEO of Aptum (Photo: Business Wire)
“Aptum means ‘adaptability’ and reflects our heritage and vision for the future,” said Susan Bowen, Chief Executive Officer of Aptum. “As businesses face exponentially increasing volumes of information, and data becomes an integral part of their infrastructure, technology platforms must adapt and harness the power of data to enable better decision making, risk evaluation and customer engagement. We help organizations unlock the potential of their data by providing a robust infrastructure that enables customers to solve complex challenges and maximize the potential of their businesses.”
Headquartered in Toronto, Aptum will operate with two focused business units — Data Center and Fiber. The Data Center business will concentrate on enabling multi-cloud services for enterprises. The Fiber business will be Canada’s first independent, neutral-host provider of small cell and 5G infrastructure, and enterprise and wholesale fiber connectivity with an extensive metro fiber network across greater Toronto and Montreal.
With a 20-year heritage helping customers maximize technologies to store, manage, move and secure their critical data, Aptum is one of a select group of companies able to offer true hybrid infrastructure solutions with secure data center, cloud, connectivity and managed services across North and Central America, Europe, the Middle East and Africa.
Aptum is led by an experienced executive team that includes:
- Susan Bowen, Chief Executive Officer
- Shenif Visram, Chief Finance Officer
- Sanjay Sachdev, President and Head of Fiber
- Leighton Plumley, Chief Revenue Officer (Data Center Business Unit)
- Cindy Jordan-Ford, EVP Global Strategic Accounts & Alliances
- Jeremy Pease, Chief Operating Officer
- Scott Davis, Interim Chief Infrastructure Officer
- Paul Dyck, Vice President, Human Resources
Concurrent with the rebranding, Aptum has launched two new offerings that expand and enhance its customers’ hybrid cloud options:
- Managed Amazon Web Services (AWS) – reinforcing Aptum’s commitment to multi-cloud this new suite of AWS services complements Aptum’s existing Managed Azure and Managed Private Cloud offerings. Managed AWS services include consultation; architecture/design; solution build and configuration; migration; project management; ongoing service management and optimization; and 24/7 expert support. Managed AWS is available in Canada, the U.S. and the U.K.
- New Cloud Connect Availability – expansion of Cloud Connect, which offers a direct, dedicated and secure connection to cloud services. Cloud Connect is now available for AWS Direct Connect, Google Cloud Platform, ServiceNow, Salesforce, SAP and Oracle in addition to Microsoft ExpressRoute. The Cloud Connect expansion is available in all regions.
“The addition of these new cloud services is a perfect example of how Aptum is continually evolving to meet our customers’ changing needs,” Bowen said. “Every business has unique considerations, constraints and objectives that will be met by different solutions. Helping customers determine the correct platform for their unique requirements and then providing expert implementation is why businesses turn to Aptum.”
“As a rapidly growing AI products company, Element AI needed a true partner that could help us focus on our business growth rather than worrying about our data center infrastructure. For the past two years, Cogeco Peer 1 has consistently delivered,” said Ludwig Gamache, IT Director, Element AI. “Our requirements are different from most companies because of the compute-intensive nature of machine learning and AI algorithms – which generate more heat to dissipate and higher power demands than average customers. Element AI is now 35 times bigger than when we launched in 2016, and Cogeco Peer 1 has been able to adapt to solve our unique challenges. We look forward to continuing to evolve our IT infrastructure with Aptum as we grow."
Resources:
- Blog post: https://aptum.com/blog/welcome-to-aptum
- More about the executive team: https://aptum.com/company/leadership-team/
- Additional assets: Logo and executive headshots
About Aptum Technologies
Aptum Technologies enables customers to unlock the potential of their data infrastructure to drive tangible business outcomes and maximize the value of their technology investments. Aptum’s Data Center, Cloud, Hosting and Connectivity solutions, underpinned with expert Managed and Professional Services, offer genuine choice and adaptability combined with international reach spanning North America, Latin America and Europe. In Canada, through its Fiber business, Aptum is the first neutral host provider of turnkey small cell connectivity, augmenting an extensive metro network across Toronto and Montreal. Aptum is a portfolio company of Digital Colony, a global investment firm dedicated to strategic opportunities in digital infrastructure. For more information, visit www.aptum.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190819005121/en/
Contact information
Cindy Watson/Mike Martin
StrategicAmpersand
AptumPR@stratamp.com
416-961-5595
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
